Keywords: novartis, signs, 10-year, ab, drug, alliance, morphosys

Novartis signs 10-year Ab drug R&D alliance with MorphoSys potentially worth up to $1.0B

Article | 10 December 2007

Print This

Swiss drug major Novartis has expanded its collaboration with German biotechnology company MorphoSys to create a broad R&D alliance ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in